McKesson Future Growth
Future criteria checks 2/6
McKesson is forecast to grow earnings and revenue by 8.7% and 7.9% per annum respectively. EPS is expected to grow by 13.6% per annum. Return on equity is forecast to be 222.4% in 3 years.
Key information
8.7%
Earnings growth rate
13.6%
EPS growth rate
| Healthcare earnings growth | 16.3% |
| Revenue growth rate | 7.9% |
| Future return on equity | 222.4% |
| Analyst coverage | Good |
| Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?
Mar 14
McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues
Feb 16Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking
Jan 29McKesson: Why The Company Is Too Richly Valued
Jan 19If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity
Nov 20McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?
Oct 30McKesson: Still Trading For A Huge Discount
Sep 06Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
Aug 21Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?
Jul 27McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
May 23Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?
Apr 17Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
Feb 22McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M
Feb 01McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price
Jan 125 Reasons Why I Am Considering Adding McKesson To My Portfolio
Dec 27McKesson Corporation: Still Trading Below Intrinsic Value
Dec 13Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus
Oct 08McKesson extends distribution partnership with CVS Health
Sep 29An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued
Sep 19McKesson to acquire Rx Savings Solutions in $875M deal
Sep 19Cardinal Health, McKesson hit 52-week highs; up 35% and 50% YTD
Aug 15McKesson raises fiscal 2023 adjusted diluted EPS following strong quarterly results
Aug 03McKesson raises dividend by 15% to $0.54/share
Jul 25McKesson Is Still An Attractive Dividend Growth Stock
Jul 10McKesson: Best Of Breed In Drug Distributor Oligopoly
Jun 20McKesson: Still Profitable Without COVID-19 Boosts
Jun 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 398,616 | 4,053 | 4,694 | 5,371 | 3 |
| 3/31/2026 | 362,950 | 3,704 | 4,859 | 5,451 | 14 |
| 3/31/2025 | 337,668 | 3,525 | 4,703 | 5,283 | 15 |
| 3/31/2024 | 311,917 | 3,034 | 3,469 | 4,011 | 15 |
| 12/31/2023 | 301,506 | 2,998 | 2,892 | 3,492 | N/A |
| 9/30/2023 | 291,098 | 3,487 | 4,306 | 4,906 | N/A |
| 6/30/2023 | 284,040 | 3,755 | 4,466 | 5,048 | N/A |
| 3/31/2023 | 276,711 | 3,563 | 4,601 | 5,159 | N/A |
| 12/31/2022 | 273,903 | 3,146 | 4,190 | 4,721 | N/A |
| 9/30/2022 | 272,027 | 2,061 | 3,952 | 4,430 | N/A |
| 6/30/2022 | 268,446 | 1,396 | 4,639 | 5,115 | N/A |
| 3/31/2022 | 263,966 | 1,119 | 3,899 | 4,434 | N/A |
| 12/31/2021 | 257,006 | 1,415 | 4,323 | 4,917 | N/A |
| 9/30/2021 | 250,991 | -4,804 | 4,098 | 4,753 | N/A |
| 6/30/2021 | 245,223 | -4,494 | 3,299 | 3,982 | N/A |
| 3/31/2021 | 238,228 | -4,538 | 3,901 | 4,542 | N/A |
| 12/31/2020 | 237,621 | -4,189 | 5,231 | 5,826 | N/A |
| 9/30/2020 | 234,194 | 2,228 | 3,905 | 4,492 | N/A |
| 6/30/2020 | 231,002 | 922 | 2,851 | 3,363 | N/A |
| 3/31/2020 | 231,051 | 906 | 3,868 | 4,374 | N/A |
| 12/31/2019 | 224,945 | -905 | 3,125 | 3,615 | N/A |
| 9/30/2019 | 221,981 | -626 | 3,066 | 3,559 | N/A |
| 6/30/2019 | 217,440 | 601 | 4,523 | 5,046 | N/A |
| 3/31/2019 | 214,319 | 33 | 3,479 | 4,036 | N/A |
| 12/31/2018 | 213,518 | -319 | 2,572 | 3,165 | N/A |
| 9/30/2018 | 210,927 | 113 | 2,751 | 3,324 | N/A |
| 6/30/2018 | 209,913 | -384 | 1,936 | 2,543 | N/A |
| 3/31/2018 | 208,357 | 62 | 3,765 | 4,345 | N/A |
| 12/31/2017 | 205,442 | 4,805 | 2,171 | 2,756 | N/A |
| 9/30/2017 | 201,955 | 4,539 | N/A | 3,155 | N/A |
| 6/30/2017 | 199,851 | 4,846 | N/A | 3,626 | N/A |
| 3/31/2017 | 198,533 | 5,194 | N/A | 4,744 | N/A |
| 12/31/2016 | 196,498 | 2,051 | N/A | 6,415 | N/A |
| 9/30/2016 | 194,267 | 2,044 | N/A | 5,349 | N/A |
| 6/30/2016 | 193,071 | 2,359 | N/A | 5,077 | N/A |
| 3/31/2016 | 190,884 | 2,290 | N/A | 3,672 | N/A |
| 12/31/2015 | 189,131 | 2,237 | N/A | 2,449 | N/A |
| 9/30/2015 | 187,716 | 2,090 | N/A | 4,198 | N/A |
| 6/30/2015 | 183,115 | 1,950 | N/A | 3,384 | N/A |
| 3/31/2015 | 179,045 | 1,775 | N/A | 3,112 | N/A |
| 12/31/2014 | 171,952 | 1,780 | N/A | 3,893 | N/A |
| 9/30/2014 | 159,804 | 1,462 | N/A | 2,488 | N/A |
| 6/30/2014 | 148,629 | 1,402 | N/A | 2,602 | N/A |
| 3/31/2014 | 137,392 | 1,419 | N/A | 3,136 | N/A |
| 12/31/2013 | 130,076 | 1,278 | N/A | 2,679 | N/A |
| 9/30/2013 | 126,839 | 1,420 | N/A | 2,837 | N/A |
| 6/30/2013 | 123,609 | 1,396 | N/A | 3,751 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MCK's forecast earnings growth (8.7% per year) is above the savings rate (2.3%).
Earnings vs Market: MCK's earnings (8.7% per year) are forecast to grow slower than the US market (14.7% per year).
High Growth Earnings: MCK's earnings are forecast to grow, but not significantly.
Revenue vs Market: MCK's revenue (7.9% per year) is forecast to grow slower than the US market (8.1% per year).
High Growth Revenue: MCK's revenue (7.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MCK's Return on Equity is forecast to be very high in 3 years time (222.4%).